Nephros Stock Analysis


USD 1.47  0.03  2.00%   

The big decline in price over the last few months for Nephrosmay encourage stockholders to take a closer look at the firm as it is trading at a share price of 1.47 on 47,700 in trading volume. The company management teams failed to add value to investors and position the firm supply of money to exploit market volatility in June. However, diversifying your holdings with Nephros or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.57. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Nephros partners.
Additionally, see Stocks Correlation.
The Nephros stock analysis report makes it easy to digest most publicly released information about Nephros and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Nephros Stock analysis module also helps to analyze the Nephros price relationship with some important fundamental indicators such as market cap and management efficiency.

Nephros Stock Analysis Notes

About 51.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.25. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Nephros recorded a loss per share of 0.39. The entity next dividend is scheduled to be issued on the 30th of September 2010. The firm had 1:20 split on the 10th of July 2019. Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey. Nephros operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 34 people. To find out more about Nephros contact Daron Evans at 201 343 5202 or learn more at

Nephros Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Nephros' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Nephros or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Nephros generated a negative expected return over the last 90 days
Nephros has high historical volatility and very poor performance
Nephros may become a speculative penny stock
Nephros has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 10.4 M. Net Loss for the year was (4.11 M) with profit before overhead, payroll, taxes, and interest of 5.74 M.
Nephros currently holds about 6.97 M in cash with (1.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.68.
Latest headline from US Stock Futures Move Higher in Premarket Session - InvestorsObserver

Nephros Upcoming and Recent Events

Earnings reports are used by Nephros to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Nephros previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report23rd of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End23rd of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Nephros Largest EPS Surprises

Earnings surprises can significantly impact Nephros' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Nephros SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Nephros prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Nephros investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Nephros specific information freely available to individual and institutional investors to make a timely investment decision.
10th of February 2022
Unclassified Corporate Event
9th of February 2022
Unclassified Corporate Event
8th of February 2022
Unclassified Corporate Event
13th of January 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
3rd of December 2021
Financial Statements and Exhibits. Changes in Registrant's Certifying Accountant
8th of October 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition

Nephros Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Nephros is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Nephros backward and forwards among themselves. Nephros' institutional investor refers to the entity that pools money to purchase Nephros' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Wexford Capital LpCommon Shares3.7 M533.7 M
Bard Associates IncCommon Shares246.4 K1.1 M
Vanguard Group IncCommon Shares123 K541 K
Cowen Prime Advisors LlcCommon Shares80.4 K354 K
Hightower Advisors LlcCommon Shares55.7 K245 K
Blair William CoCommon Shares36.2 K159 K
Elkhorn Partners Limited PartnershipCommon Shares23.7 K104 K
Note, although Nephros' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Nephros Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 15.35 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Nephros's market, we take the total number of its shares issued and multiply it by Nephros's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Nephros Profitablity

Nephros' profitability indicators refer to fundamental financial ratios that showcase Nephros' ability to generate income relative to its revenue or operating costs. If, let's say, Nephros is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Nephros' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Nephros' profitability requires more research than a typical breakdown of Nephros' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (39.47) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (41.67) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.42.

Management Efficiency

The entity has return on total asset (ROA) of (14.98) % which means that it has lost $14.98 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (25.51) %, meaning that it created substantial loss on money invested by shareholders. Nephros management efficiency ratios could be used to measure how well nephros manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 2nd of July, Nephros secures the mean deviation of 3.73, and Risk Adjusted Performance of (0.32). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Nephros, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Nephros, which can be compared to its peers in the industry. Please verify Nephros variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and semi variance to decide if Nephros is priced some-what accurately, providing market reflects its recent price of 1.47 per share. Please also check out Nephros total risk alpha, which is currently at (0.63) to check the company can sustain itself at a future point.

Nephros Price Movement Analysis

The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Simple Moving Average indicator is calculated by adding the closing price of Nephros for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Nephros short-term fluctuations and highlight longer-term trends or cycles.

Nephros Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nephros insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nephros' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Nephros insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Nephros Predictive Daily Indicators

Nephros intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Nephros stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Nephros Forecast Models

Nephros time-series forecasting models is one of many Nephros' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Nephros' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Nephros Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Nephros stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Nephros shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Nephros. By using and applying Nephros Stock analysis, traders can create a robust methodology for identifying Nephros entry and exit points for their positions.
Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells real-time water testing systems to provide actionable data on waterborne pathogens and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it offers water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and AETHER brands for the food service, hospitality, convenience store, and health care markets. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

Current Nephros Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Nephros analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Nephros analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
13.42Strong Buy3Odds
Nephros current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Nephros analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Nephros stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Nephros, talking to its executives and customers, or listening to Nephros conference calls.
Nephros Analyst Advice Details

Nephros Stock Analysis Indicators

Nephros stock analysis indicators help investors evaluate how Nephros stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Nephros shares will generate the highest return on investment. By understating and applying Nephros stock analysis, traders can identify Nephros position entry and exit signals to maximize returns.
Quick Ratio3.60
Fifty Two Week Low1.4300
Revenue Growth18.50%
Shares Short Prior Month26.76k
Average Daily Volume Last 10 Day27.04k
Average Daily Volume In Three Month50.38k
Shares Percent Shares Out0.27%
Gross Margins55.20%
Short Percent Of Float0.44%
Forward Price Earnings-4.29
Float Shares5.37M
Fifty Two Week High9.9500
Enterprise Value To Ebitda-9.31
Fifty Day Average2.3140
Two Hundred Day Average5.1814
Enterprise Value To Revenue3.66
Additionally, see Stocks Correlation. Note that the Nephros information on this page should be used as a complementary analysis to other Nephros' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for Nephros Stock analysis

When running Nephros price analysis, check to measure Nephros' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nephros is operating at the current time. Most of Nephros' value examination focuses on studying past and present price action to predict the probability of Nephros' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Nephros' price. Additionally, you may evaluate how the addition of Nephros to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Transaction History
View history of all your transactions and understand their impact on performance
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Fundamental Analysis
View fundamental data based on most recent published financial statements
Money Managers
Screen money managers from public funds and ETFs managed around the world
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Is Nephros' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nephros. If investors know Nephros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nephros listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
15.8 M
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Nephros is measured differently than its book value, which is the value of Nephros that is recorded on the company's balance sheet. Investors also form their own opinion of Nephros' value that differs from its market value or its book value, called intrinsic value, which is Nephros' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nephros' market value can be influenced by many factors that don't directly affect Nephros' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nephros' value and its price as these two are different measures arrived at by different means. Investors typically determine Nephros value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nephros' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.